Impax Pharmaceuticals Announces IPX066 Demonstrates Efficacy & Safety in APEX-PD Phase III Study in Treatment of Early Parkin...
November 18 2010 - 8:00AM
Business Wire
Impax Pharmaceuticals, the brand products division of Impax
Laboratories, Inc. (NASDAQ: IPXL), today announced positive
top-line results of the APEX-PD Phase III clinical study with
IPX066 in Parkinson’s disease (PD). IPX066 is a novel extended
release carbidopa-levodopa product. The APEX-PD results demonstrate
that IPX066 is safe and efficacious when used in patients with
early Parkinson’s disease.
The trial met its primary efficacy endpoint of change from
baseline in the sum of Unified Parkinson’s Disease Rating Scale
(UPDRS) Parts II and III score at end of study. The UPDRS Part II
measures the activities of daily living and the UPDRS Part III
measures motor symptoms of PD. All three doses of IPX066 showed
significant improvement compared to placebo (p
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From May 2024 to Jun 2024
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From Jun 2023 to Jun 2024